Raptor Pharmaceutical Corp. (NASDAQ:RPTP) has been assigned a consensus rating of “Hold” from the eight analysts that are presently covering the firm. Seven investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $8.00.

A number of brokerages have commented on RPTP. Zacks Investment Research cut Raptor Pharmaceutical Corp. from a “buy” rating to a “hold” rating in a report on Tuesday, October 25th. Cowen and Company cut Raptor Pharmaceutical Corp. from an “outperform” rating to a “market perform” rating and set a $9.00 price target for the company. in a report on Friday, September 16th. Wedbush reaffirmed a “neutral” rating and issued a $4.00 price target (down previously from $9.00) on shares of Raptor Pharmaceutical Corp. in a report on Monday, September 12th. FBR & Co reaffirmed a “hold” rating on shares of Raptor Pharmaceutical Corp. in a report on Thursday, September 8th. Finally, Citigroup Inc. cut Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and increased their price target for the company from $6.00 to $8.00 in a report on Monday, August 8th.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) opened at 9.00 on Thursday. Raptor Pharmaceutical Corp. has a 12-month low of $2.94 and a 12-month high of $9.05. The company’s 50-day moving average price is $0.00 and its 200-day moving average price is $0.00.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Fund Advisors raised its position in shares of Raptor Pharmaceutical Corp. by 5.0% in the third quarter. BlackRock Fund Advisors now owns 3,497,167 shares of the company’s stock valued at $31,370,000 after buying an additional 166,475 shares during the last quarter. Sarissa Capital Management LP raised its position in shares of Raptor Pharmaceutical Corp. by 5.5% in the second quarter. Sarissa Capital Management LP now owns 2,875,000 shares of the company’s stock valued at $15,438,000 after buying an additional 150,000 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Raptor Pharmaceutical Corp. by 2.8% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 2,284,943 shares of the company’s stock valued at $20,496,000 after buying an additional 61,499 shares during the last quarter. State Street Corp raised its position in shares of Raptor Pharmaceutical Corp. by 42.4% in the second quarter. State Street Corp now owns 1,947,089 shares of the company’s stock valued at $10,454,000 after buying an additional 580,140 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in shares of Raptor Pharmaceutical Corp. by 1.6% in the second quarter. UBS Asset Management Americas Inc. now owns 1,288,685 shares of the company’s stock valued at $6,920,000 after buying an additional 20,650 shares during the last quarter. Institutional investors own 54.88% of the company’s stock.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

5 Day Chart for NASDAQ:RPTP

Receive News & Stock Ratings for Raptor Pharmaceutical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp. and related stocks with our FREE daily email newsletter.